[Olfactory dysfunction in Parkinson's disease: its role as a new cardinal sign in early and differential diagnosis].
Olfactory dysfunction is a prominent symptom in Parkinson's disease (PD) and found in about 70-100% of patients. In earlier studies significant loss of olfactory function seemed to be unrelated to disease duration, did not correlate with motor function, and was uninfluenced by antiparkinsonian medication. We suggest that the increase of dopaminergic cells in the olfactory bulb is responsible for the hyposmia in PD patients. Interestingly, this olfactory dysfunction is not found in progressive supranuclear palsy or corticobasal degeneration. In multiple system atrophy, the deficit is mild and indistinguishable from cerebellar syndromes of other aetiologies. Intact olfaction has also been reported recently in Parkin disease (PARK 2) and vascular parkinsonism. Olfactory tests may significantly enhance the diagnostic armamentarium in the differential diagnosis of parkinsonian syndromes and indeterminate tremors. Furthermore, olfactory testing may also prove to be a useful aid in the early or "preclinical" detection of PD, once effective disease-modifying therapies are found. Braak and coworkers have confirmed the widespread, extranigral pathology in PD and suggested that pathology in the anterior olfactory region may be one of the earliest appearances of neurodegeneration in PD.
Herting
B
B
Klinik für Neurologie, Diakonie-Klinikum Schwäbisch Hall gGmbH, Diakoniestrasse 10, Schwäbisch Hall, Germany. birgit.herting@diaksha.de
Bietenbeck
S
S
Scholz
K
K
Hähner
A
A
Hummel
T
T
Reichmann
H
H
D003937:Diagnosis, Differential; D042241:Early Diagnosis; D006801:Humans; D000857:Olfaction Disorders / Q000175:diagnosis / Q000209:etiology*; D010300:Parkinson Disease / Q000175:diagnosis*; D011237:Predictive Value of Tests
Curr Opin Neurol. 2004 Aug;17(4):417-23
15247536
Neurosci Res. 2005 Jan;51(1):111-5
15596247
Neurology. 1988 Aug;38(8):1237-44
3399075
Eur Arch Otorhinolaryngol. 2000;257(4):205-11
10867835
Neurology. 1994 Feb;44(2):266-8
8309571
J Neural Transm (Vienna). 2005 Oct;112(10):1363-70
15711853
J Neurol Neurosurg Psychiatry. 1992 Feb;55(2):138-42
1538221
Exp Neurol. 2006 Jan;197(1):113-21
16246330
Nervenarzt. 2000 Aug;71(8):643-50
10996914
Brain. 2005 Jan;128(Pt 1):126-37
15548552
Chem Senses. 2003 Jul;28(6):537-43
12907591
Neurology. 2006 Mar 28;66(6):845-51
16567700
J Chronic Dis. 1975 Oct;28(9):493-7
1176578
Neuropathol Appl Neurobiol. 2003 Oct;29(5):503-10
14507342
Neurology. 1997 Nov;49(5):1424-31
9371933
Neurology. 1991 May;41(5 Suppl 2):77-80; discussion 80-1
2041598
Ann Neurol. 2001 Jul;50(1):34-41
11456307
J Neurol Neurosurg Psychiatry. 1997 May;62(5):436-46
9153598
Mov Disord. 2004 Oct;19(10):1196-202
15390014
Funct Neurol. 1998 Apr-Jun;13(2):99-103
9626594
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4154-9
11259673
J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1749-52
15548497
Cell Tissue Res. 2004 Oct;318(1):121-34
15338272
Mov Disord. 2003 Aug;18(8):938-42
12889086
J Clin Neurosci. 2002 Sep;9(5):521-4
12383407
Mov Disord. 1995 May;10(3):283-7
7651444
Neurology. 2004 Apr 13;62(7):1224-6
15079034
Ann Neurol. 1992 Jul;32(1):97-100
1642478
Ann Neurol. 2004 Aug;56(2):169-71
15293267
Mov Disord. 2003 Apr;18(4):364-72
12671941
Mov Disord. 2004 Jun;19(6):687-92
15197709
Mov Disord. 2005 Apr;20(4):471-5
15597336
J Neural Transm (Vienna). 2002 May;109(5-6):805-11
12111470
Ann Neurol. 2004 Aug;56(2):173-81
15293269
J Neural Transm (Vienna). 2005 May;112(5):669-76
15517435
Geriatrics. 1991 Aug;46 Suppl 1:47-51
1894145
Brain. 2002 Nov;125(Pt 11):2431-45
12390970
Chem Senses. 1997 Feb;22(1):39-52
9056084